Morgan Stanley’s Quoin Pharmaceuticals QNRX Stock Holding History

Morgan Stanley’s Portfolio QNRX Stock Details QNRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38.7K	Buy	8,000 +4,000	+100%	+$21.6K	﹤0.01%	6596
2026 Q1	$26.4K	Buy	4,000 +1,000	+33%	+$9.06K	﹤0.01%	6634
2025 Q4	$43.3K	Buy	+3,000	New	+$40.8K	﹤0.01%	6482
2025 Q3	–	Sell	-206	Closed	-$1.9K	–	8328
2025 Q2	$1.9K	Buy	206 +193	+1,485%	+$1.48K	﹤0.01%	7233
2025 Q1	$102	Buy	+13	New	+$171	﹤0.01%	7567
2023 Q1	–	Hold	0	–	-$111	–	7807
2022 Q4	–	Hold	0	–	–	–	7688
2022 Q3	–	Hold	0	–	–	–	7840
2022 Q1	–	Sell	-21	Closed	-$198K	–	8085
2021 Q4	$198K	Buy	+21	New	+$903K	﹤0.01%	6080
2021 Q3	–	Hold	0	–	–	–	7057
2021 Q2	–	Hold	0	–	–	–	7011
2021 Q1	–	Hold	0	–	–	–	6804
2020 Q4	–	Hold	0	–	–	–	6407
2020 Q3	–	Hold	0	–	–	–	6030
2020 Q2	–	Hold	0	–	–	–	5951
2019 Q4	–	Hold	0	–	–	–	6740
2019 Q3	–	Hold	0	–	–	–	6729
2019 Q2	–	Hold	0	–	–	–	6720
2019 Q1	–	Hold	0	–	–	–	6038
2018 Q4	–	Hold	0	–	–	–	5895
2018 Q3	–	Hold	0	–	–	–	5788
2018 Q2	–	Hold	0	–	–	–	5690
2018 Q1	–	Hold	0	–	–	–	5719
2017 Q4	–	Hold	0	–	–	–	5740
2017 Q3	–	Hold	0	–	–	–	5642
2017 Q2	–	Hold	0	–	–	–	5718
2017 Q1	–	Hold	0	–	–	–	5655

Other funds holding QNRX

DIG

Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SummitTX Capital Fort Worth, Texas $3.89B AUM 55.94% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Morgan Stanley's QNRX Position: Q2 2026 in Review

Morgan Stanley increased its Quoin Pharmaceuticals (QNRX) stake by 100% in Q2 2026, buying an estimated $21.6K and bringing the position to 8,000 shares worth $38.7K. The position accounts for ﹤0.01% of the portfolio, ranked #6596.

Morgan Stanley first reported a position in QNRX in Q4 2021 and has held it in 6 quarters since. The position peaked at $198K in Q4 2021. 20 funds tracked by Wall St. Rank hold QNRX as of Q2 2026.

Morgan Stanley held 8,000 shares of Quoin Pharmaceuticals worth $38.7K as of Q2 2026.
Morgan Stanley bought 4,000 Quoin Pharmaceuticals shares in Q2 2026, an estimated $21.6K.
Quoin Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6596 holding.
Morgan Stanley first reported a position in Quoin Pharmaceuticals in Q4 2021 and has held it in 6 quarters since.
Morgan Stanley's Quoin Pharmaceuticals position peaked at $198K in Q4 2021.
20 funds tracked by Wall St. Rank held Quoin Pharmaceuticals as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.